Sinopharm Group Co. Ltd. — Board/Management Information 2011

Jul 29, 2011

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

==> picture [57 x 70] intentionally omitted <==

*

SINOPHARM GROUP CO. LTD. 國藥控股股份有限公司

(A joint stock limited company incorporated in the People’s Republic of China with limited liability and carrying on business in Hong Kong as 國控股份有限公司 )

(Stock Code: 01099)

PROPOSED RE-ELECTION OF DIRECTORS

PROPOSED RE-ELECTION OF DIRECTORS

The Company announces that:

• (a) Mr. Wei Yulin was nominated as an executive director of the Company with effect from the date of approval by the shareholders in the EGM and until the expiration of the Next Term;

• (b) Mr. She Lulin, Mr. Wang Qunbin, Mr. Deng Jindong, Mr. Fan Banghan and Mr. Liu Hailiang were nominated as non-executive directors of the Company with effect from the date of approval by the shareholders in the EGM and until the expiration of the Next Term; and

• (c) Mr. Wang Fanghua, Mr. Tao Wuping and Mr. Xie Rong were nominated as independent nonexecutive directors of the Company with effect from the date of approval by the shareholders in the EGM and until the expiration of the Next Term.

GENERAL

A circular containing, among other matters, further details of the proposed re-election of directors together with a notice of the EGM and the form of proxy, will be dispatched to the shareholders of the Company as soon as possible.

PROPOSED RE-ELECTION OF DIRECTORS

The board of directors (the “ Board ”) of Sinopharm Group Company Limited (the “ Company* ”) currently comprises thirteen directors, being Mr. Wei Yulin, Mr. She Lulin, Mr. Wang Qunbin, Mr. Chen Wenhao, Mr. Zhou Bin, Mr. Chen Qiyu, Mr. Deng Jindong, Mr. Fan Banghan, Mr. Liu Hailiang, Mr. Wang Fanghua, Mr. Tao Wuping, Mr. Xie Rong and Mr. Zhou Bajun.

1

According to the articles of association of the Company, other than Mr. Chen Qiyu whose term of offi ce as non-executive director of the current term will expire on 30 May 2013, Mr. Chen Wenhao and Mr. Zhou Bin whose terms of offi ce as non-executive directors of the current term will both expire on 6 January 2014 and Mr. Zhou Bajun whose term of offi ce as independent non-executive director of the current term will expire on 18 August 2012, the other retiring directors will be reelected upon the approval at the extraordinary general meeting to be held on 21 September 2011 (the “ EGM ”).

The Company has nominated all of the retiring directors as candidates for the election as directors for the term of offi ce commencing from the date of the EGM to 20 September 2014 (the “ Next Term ”).

Biographical Details

Mr. Wei Yulin , aged 53, was nominated as an executive director of the Company with effect from the date of approval by the shareholders in the EGM and until the expiration of the Next Term.

Mr. Wei has around 33 years of working experience, over 16 years of which is management experience in the pharmaceutical and healthcare products industry.

Mr. Wei served as the deputy general manager of the Company from January 2003 to December 2009, Mr. Wei also served as the general manager of Sinopharm Holding Tianjin Co., Ltd ( 國藥 控股天津有限公司 ) from January 2003 to December 2003 and from October 2004 to April 2006, and its chairman from January 2004 to October 2004. Mr. Wei served as the chairman of each of Sinopharm Holding Shanxi Co., Ltd. ( 國藥控股山西有限公司 ), Sinopharm Holding Shenyang Co., Ltd. ( 國藥控股瀋陽有限公司 ), China National Pharmaceutical Group Southwest Medicine Co., Ltd. ( 國藥集團西南醫藥有限公司 ), Sinopharm Holding Hunan Co., Ltd. ( 國藥控股湖南 有限公司 ), Sinopharm Holding Zhejiang Co., Ltd. ( 國藥控股浙江有限公司 ), and Sinopharm Holding Henan Co., Ltd. ( 國藥控股河南有限公司 ) from January 2007 to January 2009, from May 2006 to January 2009, from March 2007 to January 2009, from September 2007 to January 2009, from October 2007 to January 2009 and from April 2008 to January 2009, respectively. Mr. Wei served as the general manager of the department of pharmaceutical distribution business of the Company from September 2008 to October 2009. In addition, Mr. Wei served as a director of China National Pharmaceutical Group Xinjiang Medicines Co., Ltd. ( 國藥集團新疆藥業有限公司 ) from March 2009 to August 2009. Mr. Wei has been appointed as the chairman of Sinopharm Holding Hongkong Co., Limited ( 國藥控股股份香港有限公司 ), since January 2011 and the chairman of Beijing Tianxingpuxin Bio-Med Co., Ltd. ( 北京天星普信生物醫藥有限公司 ) since April 2010. He is currently the chairman of Sinopharm Holding Beijing Huahong Co., Ltd. ( 國藥控股北京華 鴻有限公司 ). and Yujia Medical Service Co., Ltd. ( 禦佳醫療服務有限公司 ). Mr. Wei has been serving as the executive director and the president of the Company since 22 December 2008 and 20 December 2009, respectively.

Mr. Wei graduated from the Cheung Kong Graduate School of Business ( 長江商學院 ) with a degree of Executive Master of Business Administration in September 2007. Mr. Wei is a licenced pharmacist, and was qualifi ed as a senior economist in December 2009.

2

Save as disclosed herein, Mr. Wei has not held any directorship in other listed companies in the past three years nor has any relationship with any directors, senior management, substantial shareholders or controlling shareholder of the Company.

As at the date of this announcement, Mr. Wei has no interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (the “ SFO ”). Upon due appointment as an executive director of the Company, Mr. Wei will enter into a service contract with the Company for a term of three years. Mr. Wei will not receive any remuneration from the Company in his capacity as the executive director of the Company.

Save as disclosed above, the Board is not aware of any other matters in relation to the appointment of Mr. Wei that need to be brought to the attention of the shareholders nor that is required to be disclosed pursuant to Rule 13.51(2)(h)to (v)of the Rules Governing the Listing of Securities (the “ Hong Kong Listing Rules ”) on The Stock Exchange of Hong Kong Limited (the “ Hong Kong Stock Exchange ”).

Mr. She Lulin , aged 54, was nominated as a non-executive director of the Company with effect from the date of approval by the shareholders in the EGM and until the expiration of the Next Term.

Mr. She has around 27 years of working experience, over 24 years of which is management experience in the pharmaceutical and healthcare products industry.

Mr. She served as the deputy head of the general manager’s offi ce, assistant to the general manager, deputy general manager and general manager of China National Pharmaceutical Group Guangzhou Corporation ( 中國醫藥集團廣州公司 ) (“ CNPGC ”) from January 1985 to August 1996. Mr. She also served as the general manager of China National Pharmaceutical Industry Corporation Limited ( 中國醫藥工業有限公司 ) and the vice chairman of CNPGC from August 1996 to December 1998 and from December 1998 to October 2004, respectively. Mr. She has been a director, general manager and the legal representative of CNPGC since December 1998, December 1998 and September 2007, respectively. Mr. She served as the chairman of China National Medicines Co., Ltd. ( 國藥集團藥業股份有限公司 , a company listed on the Shanghai Stock Exchange) from December 1999 to January 2001. Mr. She has been the chairman and the legal representative of Sinopharm Industrial Investment Co., Ltd. ( 國藥產業投資有限公司 ) since July 2008 and the vice chairman of CNPGC since November 2009. Mr. She has been serving as the non-executive director of the Company since 8 January 2003, and he also served as the vice chairman of the Company previously and has served as the Chairman of the Company since 30 August 2007.

Mr. She graduated from Nanjing Pharmaceutical Institution ( 南京藥學院，currently known as China Pharmaceutical University), with a bachelor’s degree in science, majoring in Pharmacy in July 1982 and a degree of Executive Master of Business Administration from Tsinghua University ( 清華大學 ) in July 2005.

Save as disclosed herein, Mr. She has not held any directorship in other listed companies in the past three years nor has any relationship with any directors, senior management, substantial shareholders or controlling shareholder of the Company.

3

As at the date of this announcement, Mr. She has no interest in the shares of the Company within the meaning of Part XV of the SFO. Upon due appointment as a non-executive director of the Company, Mr. She will enter into a service contract with the Company for a period of three years. Mr. She will not receive any remuneration from the Company in his capacity as the non-executive director of the Company.

Save as disclosed above, the Board is not aware of any other matters in relation to the appointment of Mr. She that need to be brought to the attention of the shareholders nor that is required to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Hong Kong Listing Rules.

Mr. Wang Qunbin , aged 41, was nominated as a non-executive director of the Company with effect from the date of approval by the shareholders in the EGM and until the expiration of the Next Term.

Mr. Wang has around 18 years of working experience, over 15 years of which is management experience in biological medicine.

Mr. Wang was previously a lecturer at the Genetic Research Institute of Fudan University ( 復旦 大學 ) from September 1991 to September 1993, and then the general manager of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ( 上海復星醫藥 ( 集團 ) 股份有限公司 , a company listed on the Shanghai Stock Exchange) from October 1993 to October 2007 and a director of Tianjin Pharmaceutical Holdings Ltd. ( 天津藥業集團有限公司 ) from March 2001 to February 2009. Mr. Wang has been the chairman of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ( 上海復 星醫藥 ( 集團 ) 股份有限公司 , a company listed on the Shanghai Stock Exchange) since October 2007, a director and the president of Shanghai Fosun High Technology (Group) Co., Ltd. ( 上海 復星高科技 ( 集團 ) 有限公司 ) since November 1994 and January 2009, respectively, as well as a director of Shanghai Friendship-Fortune Holding Co., Ltd. ( 上海友誼復星 ( 控股 ) 有限公 司 ) and Sinopharm Industrial Investment Co., Ltd. ( 國藥產業投資有限公司 ) since September 2000 and July 2008, respectively. Mr. Wang has been a director of Shanghai Friendship Group Incorporated Co., Ltd. ( 上海友誼集團股份有限公司 ) (a company listed on the Shanghai Stock Exchange) since September 2000 and Henan Lingrui Pharmaceutical Company Ltd. ( 河南羚銳製 藥股份有限公司 ) (a company listed on the Shanghai Stock Exchange) since May 2003, and has also been an executive director and the president of Fosun International Limited ( 復星國際有限公 司 ) (a company listed on the Hong Kong Stock Exchange) since August 2005 and January 2009, respectively. Mr. Wang has been serving as the non-executive director of the Company since 8 January 2003.

Mr. Wang graduated from Fudan University with a bachelor’s degree in science majoring in genetics in July 1991. Mr. Wang is currently the vice chairman of China Pharmaceutical Industry Association, the chairman of the Shanghai Biopharmaceutics Industry Association and the chairman of the Huzhou Chambe of Commerce in Shanghai.

Save as disclosed herein, Mr. Wang has not held any directorship in other listed companies in the past three years nor has any relationship with any Directors, senior management, substantial shareholders or controlling shareholder of the Company.

4

As at the date of this announcement, Mr. Wang has no interest in the shares of the Company within the meaning of Part XV of the SFO. Upon due appointment as a non-executive Director of the Company, Mr. Wang will enter into a service contract with the Company for a period of three years. Mr. Wang will not receive any remuneration from the Company in his capacity as the non-executive director of the Company.

Save as disclosed above, the Board is not aware of any other matters in relation to the appointment of Mr. Wang that need to be brought to the attention of the Shareholders nor that is required to be disclosed pursuant to Rule 13.51(2)(h)to (v)of the Hong Kong Listing Rules.

Mr. Deng Jindong , aged 46, was nominated as a non-executive director of the Company with effect from the date of approval by the shareholders in the EGM and until the expiration of the Next Term.

Mr. Deng has over 23 years of working experience, over 18 years of which is fi nancial management experience.

Mr. Deng was previously the chief fi nancial offi cer of Economic Information Network Data Co., Ltd. ( 中經網數據有限公司 ), senior audit manager of Taikang Life Insurance Co., Ltd. ( 泰康人 壽保險股份有限公司 ) and the head of the accounting department of CNPGC from April 2000 to October 2001, from October 2001 to October 2002 and from October 2002 to October 2004, respectively. Mr. Deng has been the chief accountant of CNPGC since October 2004 and a director and the chief fi nancial offi cer of Sinopharm Industrial Investment Co., Ltd. since July 2008. Mr. Deng has also been a director of China National Pharmaceutical Group Xinjiang Medicines Co., Ltd. since March 2009. Mr. Deng has been serving as the non-executive director of the Company since 30 August 2007.

Mr. Deng graduated from Hangzhou Electronics Industry Institution ( 杭州電子工業學院 , currently known as Hangzhou Dianzi University) with a bachelor’s degree in economics in July 1986, majoring in industrial accounting. He obtained a master’s degree in economics from Central Institute of Finance and Economics ( 中央財政金融學院 , currently known as Central University of Finance & Economics) in January 1991. He is a non-practicing PRC certifi ed public accountant.

Save as disclosed herein, Mr. Deng has not held any directorship in other listed companies in the past three years nor has any relationship with any directors, senior management, substantial shareholders or controlling shareholder of the Company.

As at the date of this announcement, Mr. Deng has no interest in the shares of the Company within the meaning of Part XV of the SFO. Upon due appointment as a non-executive director of the Company, Mr. Deng will enter into a service contract with the Company for a period of three years. Mr. Deng will not receive any remuneration from the Company in his capacity as the non-executive director of the Company.

Save as disclosed above, the Board is not aware of any other matters in relation to the appointment of Mr. Deng that need to be brought to the attention of the shareholders nor that is required to be disclosed pursuant to Rule 13.51(2)(h)to (v) of the Hong Kong Listing Rules.

5

Mr. Fan Banghan , aged 57, was nominated as a non-executive director of the Company with effect from the date of approval by the shareholders in the EGM and until the expiration of the Next Term.

Mr. Fan has around 30 years of working experience, over 24 years of which is management experience in the pharmaceutical and healthcare products industry.

Mr. Fan was a deputy general manager of Shanghai Pharmaceutical Co., Ltd. ( 上海市醫藥股 份有限公司 ) (a company listed on the Shanghai Stock Exchange) from January 1998 to March 2000 and a supervisor of China National Medicines Co., Ltd. (a company listed on the Shanghai Stock Exchange) from December 2005 to May 2009. Mr. Fan has been a deputy general manager of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ( 上海復星醫藥（集團）股份有限公司 , a company listed on the Shanghai Stock Exchange) since 2000 and a director of China National Medicines Co., Ltd. since May 2009. Mr. Fan has been a director and the general manager of Sinopharm Industrial Investment Co., Ltd. since July 2008. Mr. Fan has been serving as the nonexecutive director of the Company since 8 January 2003.

Mr. Fan graduated from Branch Institute of the Shanghai Education Institute ( 上海教育學院 ) and obtained an associate education, majoring in politics and education, in July 1984. Mr. Fan is currently the vice chairman of the Shanghai Pharmaceutical Trade Association ( 上海醫藥商業行業 協會 ).

Save as disclosed herein, Mr. Fan has not held any directorship in other listed companies in the past three years nor has any relationship with any directors, senior management, substantial shareholders or controlling shareholder of the Company.

As at the date of this announcement, Mr. Fan has no interest in the shares of the Company within the meaning of Part XV of the SFO. Upon due appointment as a non-executive director of the Company, Mr. Fan will enter into a service contract with the Company for a period of three years. Mr. Fan will not receive any remuneration from the Company in his capacity as the non-executive director of the Company.

Save as disclosed above, the Board is not aware of any other matters in relation to the appointment of Mr. Fan that need to be brought to the attention of the shareholders nor that is required to be disclosed pursuant to Rule 13.51(2)(h)to (v) of the Hong Kong Listing Rules.

Mr. Liu Hailiang , aged 61, was nominated as a non-executive director of the Company with effect from the date of approval by the shareholders in the EGM and until the expiration of the Next Term.

He has around 41 years of working experience, over 14 years of which is management experience.

Mr. Liu served as the human resources manager of Johnson & Johnson China Ltd. ( 強生公司 ( 中 國 ) 有限公司 ) from March 1995 to March 2000. Mr. Liu was an assistant to the general manager and chief human resources offi cer of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ( 上海復星 醫藥（集團）股份有限公司 , a company listed on the Shanghai Stock Exchange) from March 2000 to May 2004, and has been a supervisor of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ( 上海 復星醫藥（集團）股份有限公司 , a company listed on the Shanghai Stock Exchange) since May 2004 and has been the chairman of the supervisory committee since May 2008. Mr. Liu has been serving as the non-executive director of the Company since 8 January 2003.

6

Mr. Liu graduated from Shanghai Construction Institute and obtained an associate education in business administration in September 1986.

Save as disclosed herein, Mr. Liu has not held any directorship in other listed companies in the past three years nor has any relationship with any directors, senior management, substantial shareholders or controlling shareholder of the Company.

As at the date of this announcement, Mr. Liu has no interest in the shares of the Company within the meaning of Part XV of the SFO. Upon due appointment as a non-executive director of the Company, Mr. Liu will enter into a service contract with the Company for a period of three years. Mr. Liu will not receive any remuneration from the Company in his capacity as the non-executive director of the Company.

Save as disclosed above, the Board is not aware of any other matters in relation to the appointment of Mr. Liu that need to be brought to the attention of the shareholders nor that is required to be disclosed pursuant to Rule 13.51(2)(h)to (v) of the Hong Kong Listing Rules.

Mr. Wang Fanghua , aged 63, was nominated as an independent non-executive director of the Company with effect from the date of approval by the shareholders in the EGM and until the expiration of the Next Term.

Mr. Wang has 41 years of working experience.

Mr. Wang worked at Fudan University as the head of the Faculty of Business Administration of the School of Management from July 1994 to July 1998. He has been the dean of Antai College of Economics & Management of Shanghai Jiao Tong University ( 上海交通大學 ) since January 2003. Mr. Wang was an independent director of Shanghai Jinjiang International Hotels Development Co., Ltd. ( 上海錦江國際酒店發展股份有限公司 ) (a company listed on the Shanghai Stock Exchange) from August 2003 to May 2009. Mr. Wang has been an independent director of each of Shanghai Oriental Pearl Co., Ltd. ( 上海東方明珠（集團）股份有限公司 ) (a company listed on the Shanghai Stock Exchange), Shenzhen Auto Electric Power Plant Co., Ltd. ( 深圳奧特迅電力設備股份有限 公司 ) (a company listed on the Shenzhen Stock Exchange) and Shanghai New World Co., Ltd. ( 上 海新世界股份有限公司 ) (a company listed on the Shanghai Stock Exchange) since June 2005, March 2007 and June 2008, respectively. He has also been an independent non-executive director of Lonking Holdings Limited ( 中國龍工控股有限公司 ) (a company listed on the Hong Kong Stock Exchange) since May 2008. Mr. Wang has been serving as the independent non-executive director of the Company since 16 January 2003.

Mr. Wang graduated from Fudan University with a master’s degree in economics in January 1989.

Save as disclosed herein, Mr. Wang has not held any directorship in other listed companies in the past three years nor has any relationship with any directors, senior management, substantial shareholders or controlling shareholder of the Company.

7

As at the date of this announcement, Mr. Wang has no interest in the shares of the Company within the meaning of Part XV of the SFO. Upon due appointment as an independent non-executive director of the Company, Mr. Wang will enter into a service contract with the Company for a period of three years. Mr. Wang will not receive any remuneration from the Company in his capacity as the independent non-executive director of the Company.

Save as disclosed above, the Board is not aware of any other matters in relation to the appointment of Mr. Wang that need to be brought to the attention of the shareholders nor that is required to be disclosed pursuant to Rule 13.51(2)(h)to (v) of the Hong Kong Listing Rules.

Mr. Tao Wuping , aged 55, was nominated as an independent non-executive director of the Company with effect from the date of approval by the shareholders in the EGM and until the expiration of the Next Term.

Mr. Tao has around 38 years of working experience, over 24 years of which is for practising law.

Mr. Tao has been the head of Shen Da Law Firm ( 申達律師事務所 ), a visiting law professor of Shanghai Institute of Foreign Trade ( 上海對外貿易學院 ), a part-time professor at the Law and Politics College of East China Normal University ( 華東師範大學 ), and the honorary dean and a part-time professor at the Law and Politics College of Shanghai Normal University ( 上海師範大 學 ) since August 1994, March 2002, June 2003, and September 2003, respectively. Mr. Tao has been serving as the independent non-executive director of the Company since 16 January 2003.

Mr. Tao graduated from Fudan University with a master’s degree in law, majoring in international economic law, in June 1997. Mr. Tao is a lawyer. Mr. Tao was recognized as the “National Outstanding Attorney at Law” by All China Lawyers Association and the fi rst session of “Eastern Attorney at Law” by Shanghai Bar Association ( 上海律師協會 ).

Save as disclosed herein, Mr. Tao has not held any directorship in other listed companies in the past three years nor has any relationship with any directors, senior management, substantial shareholders or controlling shareholder of the Company.

As at the date of this announcement, Mr. Tao has no interest in the shares of the Company within the meaning of Part XV of the SFO. Upon due appointment as an independent non-executive director of the Company, Mr. Tao will enter into a service contract with the Company for a period of three years. Mr. Tao will not receive any remuneration from the Company in his capacity as the independent non-executive director of the Company.

Save as disclosed above, the Board is not aware of any other matters in relation to the appointment of Mr. Tao that need to be brought to the attention of the shareholders nor that is required to be disclosed pursuant to Rule 13.51(2)(h)to (v) of the Hong Kong Listing Rules.

8

Mr. Xie Rong , aged 58, was nominated as an independent non-executive director of the Company with effect from the date of approval by the shareholders in the EGM and until the expiration of the Next Term.

Mr. Xie has around 41 years of working experience.

He served as the deputy head of the Accounting Department of Shanghai University of Finance & Economics ( 上海財經大學 ) and a partner of KPMG China ( 畢馬威華振 ) from September 1994 to November 1997 and from December 1997 to October 2002, respectively. Mr. Xie has been a director of SAIC Motor Co., Ltd. ( 上海汽車股份有限公司 ) (a company listed on the Shanghai Stock Exchange) since April 2003 and was its independent director from April 2003 to June 2008. Mr. Xie served as an independent non-executive director of China Shipping Development Co., Ltd. ( 中海發展股份有限公司 ) (a company listed on the Hong Kong Stock Exchange and the Shanghai Stock Exchange) from May 2003 to May 2009. He has been an independent non-executive director of each of China Eastern Airlines Corporation Limited ( 中國東方航空股份有限公司 ) (a company listed on the Hong Kong Stock Exchange and the Shanghai Stock Exchange), China CITIC Bank Corporation Limited ( 中信銀行股份有限公司 ) (a company listed on the Hong Kong Stock Exchange and the Shanghai Stock Exchange) and Tianjin Capital Environmental Protection Group Co., Ltd. ( 天津創業環保集團股份有限公司 ) (a company listed on the Hong Kong Stock Exchange and the Shanghai Stock Exchange) since June 2003, February 2007 and April 2008, respectively. Mr. Xie has been serving as the independent non-executive director of the Company since 30 August 2007.

Mr. Xie graduated from Shanghai University of Finance & Economics ( 上海財經大學 ) with a doctorate degree in economics, majoring in accounting, in January 1993. Mr. Xie is currently the vice president of the Shanghai National Accounting Institute ( 上海國家會計學院 ), a member of the Master of National Accounting Professional Education Guidance Committee of the Degree Committee of the State Council ( 國務院學位委員會全國會計碩士專業學位教育指導委員會 ), a standing commissioner of the China Auditing Institute ( 中國審計學會 ) and standing commissioner of the China Accounting Institute ( 中國會計學會 ).

Save as disclosed herein, Mr. Xie has not held any directorship in other listed companies in the past three years nor has any relationship with any directors, senior management, substantial shareholders or controlling shareholder of the Company.

As at the date of this announcement, Mr. Xie has no interest in the shares of the Company within the meaning of Part XV of the SFO. Upon due appointment as an independent non-executive director of the Company, Mr. Xie will enter into a service contract with the Company for a period of three years. Mr. Xie will not receive any remuneration from the Company in his capacity as the independent non-executive director of the Company.

Save as disclosed above, the Board is not aware of any other matters in relation to the appointment of Mr. Xie that need to be brought to the attention of the shareholders nor that is required to be disclosed pursuant to Rule 13.51(2)(h)to (v) of the Hong Kong Listing Rules.

9

GENERAL

A circular containing, among other matters, further details of the proposed re-election of directors together with a notice of the EGM and the form of proxy, will be dispatched to the shareholders of the Company as soon as possible.

By order of the Board Sinopharm Group Co. Ltd. She Lulin Chairman

Shanghai, the PRC

29 July 2011

As at the date of this announcement, the executive director of the Company is Mr. Wei Yulin; the non-executive directors of the Company are Mr. She Lulin, Mr. Wang Qunbin, Mr. Chen Wenhao, Mr. Zhou Bin, Mr. Chen Qiyu, Mr. Deng Jindong, Mr. Fan Banghan and Mr. Liu Hailiang; and the independent non-executive directors of the Company are Mr. Wang Fanghua, Mr. Tao Wuping, Mr. Xie Rong and Mr. Zhou Bajun.

• The Company is registered as a non-Hong Kong company under Part XI of the Companies Ordinance (Chapter 32 of the Laws of Hong Kong) under its Chinese name and the English name “Sinopharm Group Co. Ltd.”

10